Media Release

Cordlife Returns to Profitability in 1QFY2018

- S$53.9 million in cash, fixed deposits and short-term funds investments as at 30 September 2017
- Group actively exploring acquisition opportunities in Asia

<table>
<thead>
<tr>
<th></th>
<th>1QFY2018 (S'$000)</th>
<th>1QFY2017 (S'$000)</th>
<th>Change (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Revenue</td>
<td>16,589</td>
<td>14,653</td>
<td>13.2</td>
</tr>
<tr>
<td>Gross Profit</td>
<td>11,012</td>
<td>9,489</td>
<td>15.9</td>
</tr>
<tr>
<td>Pre-tax Operating Profit</td>
<td>925</td>
<td>799</td>
<td>15.8</td>
</tr>
<tr>
<td>Net Profit/(Loss) Attributable to Shareholders</td>
<td>649</td>
<td>(574)</td>
<td>n.m.</td>
</tr>
</tbody>
</table>

SINGAPORE, 10 November 2017 – Cordlife Group Limited ("Cordlife", and together with its subsidiaries, the “Group”) said today it returned to profitability in its fiscal first quarter ended 30 September 2017 ("1QFY2018"), following a loss in the same period last year ("1QFY2017"), thanks to increased demand for the storage of cord blood and cord lining stem cells and an absence of non-operational finance costs.

The consumer healthcare company, a pioneer in Asia’s private cord blood banking industry, made a net profit attributable to shareholders of S$649,000 in 1QFY2018. It incurred a net loss of S$574,000 in 1QFY2017.

The turnaround came on the back of a 13.2% rise in revenue to S$16.6 million as the number of newborn deliveries grew to 6,700 in 1QFY2018 from 6,300 in 1QFY2017. Cordlife also benefited from an absence of non-operational finance costs, which ate into its bottom line in 1QFY2017, after it redeemed and cancelled the remaining S$68.25 million worth of fixed-rate notes in FY2017. The notes were sold in 2014 as part of the Group’s multi-currency debt issuance programme.

Gross profit margin edged up to 66.3% in 1QFY2018 from 64.8% in 1QFY2017 as the Group gave lower discounts in India and the Philippines. Pre-tax operating profit rose 15.8% to S$0.9 million.

Fully diluted earnings per share for 1QFY2018 came to 0.26 Singapore cents (1QFY2017: loss per share of 0.22 Singapore cents), while net asset value per share amounted to 47.20 Singapore cents as at 30 September 2017, compared to 48.31 Singapore cents as at 30 June 2017. The Group had S$53.9 million in cash and cash equivalents, fixed deposits and short-term investments in money market funds as at 30 September 2017.
Cordlife, which operates in eight markets in Asia, “is actively exploring acquisition and investment opportunities to augment its market leadership in the region,” according to Dr Wong Chiang Yin, the Group’s Chief Executive Officer.

The Group is also looking to expand its diagnostics business, which currently offers non-invasive prenatal testing, urine-based metabolic screening for newborns, and paediatric vision screening for children aged six months to six years.

### End ###

**Media & Investor Contact Information**

WeR1 Consultants Pte Ltd  
3 Phillip Street, #12-01, Royal Group Building  
Singapore 048693  
Tel: (65) 6737 4944  
Frankie Ho – frankieho@wer1.net  
Grace Yew – graceyew@wer1.net  
Afina Kong – afinakong@wer1.net

**About Cordlife Group Limited**  
(Bloomberg: CLGL; Reuters: CORD.SI)

Incorporated in May 2001, Cordlife is a leading provider of cord blood, cord tissue and umbilical cord lining banking services in Asia.

As a consumer healthcare company catering to, among others, the mother and child segment, Cordlife has the largest market share among private cord blood banks in Singapore, the Philippines and Indonesia. It is among the top three market leaders in Hong Kong and India. In February 2017, Cordlife increased its shareholding in Stemlife Berhad, the largest cord blood bank in Malaysia and the latest addition to the subsidiaries of the Group, to 99.03%. Cordlife is also the first Singapore-headquartered private cord blood bank in Myanmar and Vietnam.

Cordlife’s cord blood and cord lining processing and cryopreservation facility in Singapore is one of only six private cord blood banks in the world to be dually accredited by AABB and FactNetcord, two of the world’s gold standards for cord blood banking. The Group’s majority-owned Hong Kong Screening Centre Limited and Cordlife Sciences (India) Pvt Ltd have also received accreditation from the College of American Pathologists, which only recognises facilities that meet or exceed the highest standards in laboratory services. Cordlife has been listed on the Mainboard of the Singapore Exchange since March 2012.

For more information, visit [http://cordlife.listedcompany.com](http://cordlife.listedcompany.com)